The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A therapeutic composition comprising:

an injectable biodegradable carrier, said carrier comprising a first polysaccharide cross-linked to a second polysaccharide, wherein said first and second polysaccharides is each a member selected from the group consisting of hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, heparin heparan sulfate and alginate; and wherein said first and second polysaccharides are covalently cross-linked to each other through imine bonds between amino groups on said second polysaccharide and aldehyde groups from oxidized sugar rings on said first polysaccharide; and

a therapeutic agent selected from the group consisting of growth factors, cytokines, hormones, DNA constructs, and autologous, allogenic or modified cells.

- 2. (original) The composition of claim 1, wherein said first polysaccharide is the same as said second polysaccharide.
- 3. (original) The composition of claim 2, wherein said first and said second polysaccharide are both hyaluronate.
- 4. (original) The composition of claim 1, wherein said first polysaccharide is different from said second polysaccharide.
- 5. (original) The composition of claim 4, wherein said first polysaccharide is hyaluronate and said second polysaccharide is chondroitin sulfate.
- 6. (original) The composition of claim 1, wherein said first polysaccharide contains an excess of aldehyde groups such that free aldehyde groups remain subsequent to cross-linking to said second polysaccharide.
- 7. (original) The composition of claim 1, wherein said carrier has a gel-like form.
 - 8. (cancelled)

- 9. (original) The composition of claim 1, wherein said therapeutic agent is covalently bonded to said carrier.
- 10. (original) The composition of claim 1, wherein said therapeutic agent is entrapped within said carrier.
- 11. (original) The composition of claim 1, wherein said therapeutic agent is a chondrogenic agent.
 - 12-28 (cancelled).